Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revamilast in Chronic Persistent Asthma
NCT01436890Phase 2Completed
- Sponsor
- Glenmark Pharmaceuticals
- Start
- Oct 2011
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of revamilast in asthma (4 arms), sponsored by Glenmark Pharmaceuticals. Primary endpoint: Forced Expiratory Volume in One Second at 12 weeks. Started Oct 2011; status: completed.
02
Drugs
revamilast
03
Conditions
asthma
Beyond the preview
Go deeper on NCT01436890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01436890.